AN2 Therapeutics Signs Grant Agreement To Discover Boron Based Therapies for Tuberculosis, Malaria
Portfolio Pulse from Benzinga Newsdesk
AN2 Therapeutics has signed a grant agreement to discover boron-based therapies for tuberculosis and malaria. The company's stock symbol is ANTX.
September 26, 2023 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The grant agreement signed by AN2 Therapeutics could potentially lead to the discovery of new therapies for tuberculosis and malaria, which could positively impact the company's stock.
The grant agreement could lead to the discovery of new therapies, which could increase the company's product portfolio and potentially its revenues. This could positively impact the company's stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100